Missense mutations in LRRK2 were first identified as a cause of Parkinson’s disease (PD) in 2004. Subsequent studies showed that these mutations account for up to 10 percent of familial cases, with ...

Score another one for amyloid immunotherapy. The anti-pyroglutamated amyloid antibody donanemab has posted positive top-line results in the Phase 3 Trailblazer-Alz2 study, according to an Eli Lilly ...

It has been clear for a while that anti-amyloid antibodies can sweep plaque from the brain, but until now the question of whether this slows cognitive decline has remained hotly contended. Despite ...

This database is a repository of normal genetic variability, designed to be a tool for researchers who study neurodegenerative disease. It contains whole-exome sequencing results from nearly 500 ...

Today, Biogen and Eisai announced they would terminate the Phase 3 ENGAGE and EMERGE trials of aducanumab for early Alzheimer’s disease. A futility analysis run by an independent data-monitoring ...

Will Biogen’s aducanumab become the first drug approved to slow progression of Alzheimer’s disease? Biogen’s licensing application for the biologic ran into headwinds at a U.S. Food and Drug ...

Eisai and Biogen yesterday announced positive topline results from the Phase 3 Clarity trial of their anti-amyloid antibody lecanemab. The drug slowed decline on the primary endpoint, CDR-SB, by 27 ...

The first direct-to-consumer Alzheimer’s disease blood test has arrived. Quest Diagnostics, a worldwide diagnostic service headquartered in Secaucus, New Jersey, announced on July 31 that it would ...

Buoyed by data crediting amyloid removal with ever-so-slightly slowed cognitive decline, many scientists are now optimistic about the prospects for anti-amyloid immunotherapy. Four “-mabs”—of the ...

With anti-amyloid antibodies now consistently hitting their target, tau immunotherapy represents the next frontier. In Alzheimer’s disease, tau tangles correlate far more closely with cognitive ...

In Alzheimer’s disease, defective autophagy seeds Aβ fibrils around the nuclei of neurons, which then burst, leaving amyloid plaques in their wake. This is according to researchers led by Ralph Nixon ...

A potential treatment for Alzheimer’s disease relies on 40 Hz light or sound to entrain gamma rhythms in the brain. This intervention, pioneered by Li-Huei Tsai and colleagues at Massachusetts ...